A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Clinical trial NCT03301220 · COMPLETED
Trial details
- NCT number
- NCT03301220
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-07
- Primary completion
- 2024-05-01
- Enrollment
- 390
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.